Details of the Drug
General Information of Drug (ID: DMFWKG1)
Drug Name |
Nandrolone
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
Decadura; Estrenolone; Menidrabol; Nadrolone; Nandrolon; Nandrolona; Nandrolonum; Norandrostenolon;Norandrostenolone; Nortestonate; Nortestosterone; Nortestosteronum; Oestrenolon; LT03330030; U 2410; Decadura (TN); Durabolin (TN); Nandrolona [INN-Spanish]; Nandrolone (INN); Nandrolonum [INN-Latin]; Estr-4-en-3-one, 17beta-hydroxy-(8CI); Estr-4-en-3-one, 17-hydroxy-, (17beta)-(9CI); Estr-4-en-3-one, 17-hydroxy-, (17-beta)-(9CI); (17-beta)-17-Hydroxyestr-4-en-3-one; (17beta)-17-hydroxyestr-4-en-3-one; (8R,9S,10R,13S,14S,17S)-17-hydroxy-13-methyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-one; 17-Hydroxy-Estr-4-Ene-3-One; 17-beta-Hydroestr-4-en-3-one; 17beta-Hydroxy-19-nor-4-androsten-3-one; 17beta-Hydroxy-19-norandrost-4-en-3-one; 17beta-Hydroxy-4-estren-3-one; 17beta-hydroxy-19-nor-4-androsten-3-one; 17beta-hydroxy-4-estren-3-one; 17beta-hydroxyestr-4-en-3-one; 19-Norandrostenolone; 19-Nortestosterone; 4-Estren-17beta-ol-3-one; 4-estren-17beta-ol-3-one
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Therapeutic Class |
Anabolic Agents
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 274.4 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.6 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 0 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Drug-Metabolizing Enzyme (DME) |
|
|||||||||||||||||||||||||||||||||||||||||
Drug Off-Target (DOT) |
|
|||||||||||||||||||||||||||||||||||||||||
Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Osteoporosis | |||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | FB83.0 | |||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||||||||
References